Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV
Committee on Infectious Diseases and Committee … - …, 1998 - publications.aap.org
The Food and Drug Administration recently approved the use of palivizumab (palē-vizhū-
mäb), an intramuscularly administered monoclonal antibody preparation …
mäb), an intramuscularly administered monoclonal antibody preparation …
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV
NA Halsey, JS Abramson, PJ Chesney… - …, 1998 - augusta.elsevierpure.com
Abstract The Food and Drug Administration recently approved the use of palivizumab (pale-
vizhumab), an intramuscularly administered monoclonal antibody preparation …
vizhumab), an intramuscularly administered monoclonal antibody preparation …
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
Committee on Infectious Diseases and Committee … - …, 2003 - publications.aap.org
This Policy Statement was retired October 2006. Palivizumab and Respiratory Syncytial
Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug …
Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug …
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
American Academy of Pediatrics Committee on … - Pediatrics, 2003 - cir.nii.ac.jp
抄録< jats: p> Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous
(RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe …
(RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe …
From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
Committee on Infectious Diseases - Pediatrics, 2009 - pubmed.ncbi.nlm.nih.gov
Palivizumab was licensed in June 1998 by the US Food and Drug Administration for
prevention of serious lower respiratory tract disease caused by respiratory syncytial virus …
prevention of serious lower respiratory tract disease caused by respiratory syncytial virus …
Prevention of respiratory syncytial virus infections in high‐risk infantsby monoclonal antibody (palivizumab)
JR Groothuis, H Nishida - Pediatrics International, 2002 - Wiley Online Library
Respiratory syncytial virus (RSV) is a major viral pathogen whichcauses serious respiratory
illness in infants and children worldwide. Palivizumab (Synagis) is an anti‐RSV monoclonal …
illness in infants and children worldwide. Palivizumab (Synagis) is an anti‐RSV monoclonal …
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
B Resch - Human vaccines & immunotherapeutics, 2017 - Taylor & Francis
Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in
children below the age of 5 y. It is associated with up to 63% of all acute respiratory …
children below the age of 5 y. It is associated with up to 63% of all acute respiratory …
Cost‐effectiveness of respiratory syncytial virus prophylaxis with palivizumab
CA Reeve, JS Whitehall, PG Buettner… - … of paediatrics and …, 2006 - Wiley Online Library
Background: A monoclonal antibody, palivizumab, directed against respiratory syncytial
virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the …
virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the …
Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
Committee on Infectious Diseases - Pediatrics, 2009 - publications.aap.org
This Policy Statement was retired January 2013. Palivizumab was licensed in June 1998 by
the US Food and Drug Administration for prevention of serious lower respiratory tract …
the US Food and Drug Administration for prevention of serious lower respiratory tract …
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
HC Meissner, SS Long… - …, 2003 - publications.aap.org
Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are
licensed by the Food and Drug Administration for use in preventing severe respiratory …
licensed by the Food and Drug Administration for use in preventing severe respiratory …